Recombinant metapneumovirus F proteins and their use

US11027007B2 · kind B2 · utility

Assignees

• The United States of America, as represented by the Secretary, Department of Health and Human Services · US
• Institute for Research in Biomedicine · CH

Inventors

• Peter Kwong · Washington, US
• Michael Gordon Joyce · Washington, US
• Baoshan Zhang · Bethesda, US
• Yongping Yang · Potomac, US
• Peter L. Collins · Kensington, US
• Ursula Buchholz · Silver Spring, US
• Davide Corti · Bellinzona, CH
• Antonio Lanzavecchia · Bellinzona, CH
• Guillaume Stewart-Jones · Cambridge, US

Key dates

• Filing date: Sep 23, 2019
• Grant date: Jun 8, 2021
• Expiry date: Dec 2, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2760/18534
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Metapneumovirus (MPV) F proteins stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the MPV F proteins and/or nucleic acid molecules can be used to generate an immune response to MPV in a subject. In additional embodiments, the therapeutically effective amount of the MPV F ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing MPV infection.